Welcome to
Texas Biologics

Investing in disease prevention and treatment

Learn more about us

Photo credit: NEXU

gloved hand with test tubes


Through our innovative programs, Texas Biologics is investing in every phase of biologic development, from research support to clinical evaluation to commercialization.

Learn More
woman in lab coat working in lab

Current Projects

UT researchers are active in the development of new biologic therapies, including enzymes, antibodies, peptides and vaccines.

Learn More

Partner With Us

There are many ways to engage with Texas Biologics, from academic collaboration to technology licensing to philanthropic support.

Learn More

First Science Studios Awardees Announced

In partnership with Dell Med’s HTRI, we awarded the first Science Studios awards. A major goal of the program is to connect clinician investigators at Dell Med with scientists across the UT campus to address outstanding questions in the medical sciences.

Read more about the 2023 awardees


Patents since 2012


Raised via spinoff companies


Drugs in commercial use or development


McLellan Named Recipient of the 2024 IVI-SK Bioscience Park MahnHoon Award

Jason McLellan has been named the recipient of the International Vaccine Institutes Bioscience Park MahnHoon Award for his role in the development of numerous vaccines.

Cancer Drug Restores Immune System’s Ability to Fight Tumors

Drug candidate developed by Everett Stone and his team is effective in mice with cancers of skin, bladder, blood and colon.

Every year, millions of people become sickened by RSV, and more than 100,000 die. New vaccines with a connection to UT Austin may help turn those numbers around.